These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 6789438)
1. [The treatment of post-transfusional hemochromatosis with chelating agents]. Delvaux D; Andrien JM; Fillet G Rev Med Liege; 1981 Jun; 36(11):477-80. PubMed ID: 6789438 [No Abstract] [Full Text] [Related]
2. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis]. Giraud P; Orsini A; Giraud F; Pinsard N Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583 [No Abstract] [Full Text] [Related]
3. Clinical usefulness of iron chelating agents. Waxman HS; Brown EB Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246 [No Abstract] [Full Text] [Related]
5. [Idiopathic hemochromatosis. Therapeutics]. Pergola F Presse Med (1893); 1967 May; 75(24):1221-2. PubMed ID: 4960744 [No Abstract] [Full Text] [Related]
6. Iron excretion in thalassemia after the administration of chelating agents. Markum AH; Iskandar W; Keng KL; Odang O Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722 [No Abstract] [Full Text] [Related]
7. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis. Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924 [No Abstract] [Full Text] [Related]
8. [Recent advance in the therapy of metal poisoning with complexing agents]. Aaseth J Tidsskr Nor Laegeforen; 1972 May; 12(13):918-22. PubMed ID: 4624035 [No Abstract] [Full Text] [Related]
9. [Myocardiopathy caused by iron deposition. Treatment with chelating agents]. Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244 [No Abstract] [Full Text] [Related]
10. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man]. Bohne F; Lessmann J Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039 [No Abstract] [Full Text] [Related]
11. Chelation therapy for iron overload. Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885 [No Abstract] [Full Text] [Related]
12. Iron metabolism and chelation therapy in hemosiderosis. Graziano JH Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529 [No Abstract] [Full Text] [Related]
13. Hemochromatosis and vitamin C. Herbert V Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572 [No Abstract] [Full Text] [Related]
14. Chelating agents in medicine. Br Med J; 1971 May; 2(5756):270-2. PubMed ID: 4102017 [No Abstract] [Full Text] [Related]
16. Advances in the use of iron-chelating agents for the treatment of iron overload. Modell B Prog Hematol; 1979; 11():267-312. PubMed ID: 392593 [No Abstract] [Full Text] [Related]
18. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report. Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548 [No Abstract] [Full Text] [Related]
19. Pathogenesis and management of iron overload in thalassemia. Hershko C Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456 [No Abstract] [Full Text] [Related]
20. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis]. Spraul CW; Schicketanz C; Lang GE Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]